Chimeric Therap 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 
  • ||||||||||  CHM 1101 / Chimeric Therap
    Enrollment closed, Trial primary completion date:  CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma (clinicaltrials.gov) -  Jul 24, 2024   
    P1,  N=42, Active, not recruiting, 
    Trial primary completion date: Sep 2024 --> Aug 2025 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2024 --> Oct 2025
  • ||||||||||  CHM 2101 / Chimeric Therap
    Trial completion date, Trial initiation date, Trial primary completion date:  A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy (clinicaltrials.gov) -  Dec 21, 2023   
    P1/2,  N=135, Not yet recruiting, 
    Trial completion date: Dec 2024 --> Aug 2026 | Trial primary completion date: Jan 2024 --> Aug 2026 Trial completion date: Aug 2024 --> Jun 2027 | Initiation date: Feb 2024 --> Jun 2024 | Trial primary completion date: Aug 2024 --> Jun 2026
  • ||||||||||  CHM 1101 / Chimeric Therap
    Phase classification:  CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma (clinicaltrials.gov) -  Nov 13, 2023   
    P1,  N=42, Recruiting, 
    Trial completion date: Aug 2024 --> Jun 2027 | Initiation date: Feb 2024 --> Jun 2024 | Trial primary completion date: Aug 2024 --> Jun 2026 Phase classification: P1b --> P1
  • ||||||||||  CHM 1101 / Chimeric Therap
    Enrollment open, Trial initiation date:  CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma (clinicaltrials.gov) -  Aug 7, 2023   
    P1b,  N=42, Recruiting, 
    These studies will lead to determination of a maximum tolerated dose/maximum feasible dose. Not yet recruiting --> Recruiting | Initiation date: Feb 2023 --> Jun 2023
  • ||||||||||  CDH17 CAR-NK cell therapy / Medigen Biotech, Magicell-NK / Medigen Biotech, CHM 2301 / Chimeric Therap
    Development of allogenic nonviral RNA-based CAR-NK therapy targeting CDH17 in relapsed/refractory gastrointestinal cancer. () -  Apr 26, 2023 - Abstract #ASCO2023ASCO_4595;    
    Ex vivo expanded human peripheral blood NK (Magicell-NK, Medigen, Taiwan) cells were used in this study. Our findings suggest that a non-viral based CDH17 CAR-NK cell therapy could be a potential allogeneic, off-the-shelf CAR-NK therapy candidate in GI cancer and support the rationale of further investigating it in vivo and clinical trials.
  • ||||||||||  CLTX-CAR T cell therapy / Chimeric Therap
    Exploration of a novel toxin-incorporating CAR T cell: how does chlorotoxin recognize glioblastoma cells? (Exhibit Hall D) -  Nov 16, 2021 - Abstract #SNO2021SNO_481;    
    P1
    Diffuse distribution of CLTX.Cy5.5 was also seen in fixed xenograft sections of PBT003-4, PBT1206, PBT030-2, PBT051 and PBT138 tumor cells, and not obviously associated with more discrete staining for IL13Rα2 and EGFR. Ongoing experiments are further examining association of CLTX with other putative components of CLTX receptor complexes, and their redistribution during binding by CLTX and CLTX-CAR T cells.
  • ||||||||||  CLTX-CAR T cell therapy / Chimeric Therap
    Clinical evaluation of chlorotoxin-directed CAR T cells for patients with recurrent glioblastoma (Exhibit Hall D) -  Nov 16, 2021 - Abstract #SNO2021SNO_337;    
    P1
    Ongoing studies are evaluating biomarkers of response and resistance, including CAR T cell activation and inflammatory cytokines. This clinical study provides first-in-human evidence for the safety and feasibility of CLTX-CAR T cells as a new class of toxin-based CARs for treatment of GBM.
  • ||||||||||  CLTX-CAR T cell therapy / Chimeric Therap
    Journal, CAR T-Cell Therapy:  Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma. (Pubmed Central) -  Jun 24, 2021   
    Effective targeting by CLTX-CAR T cells requires cell surface expression of matrix metalloproteinase-2. Our results pioneer a peptide toxin in CAR design, expanding the repertoire of tumor-selective CAR T cells with the potential to reduce antigen escape.